Mechanism of action deconvolution of the small-molecule pathological tau aggregation inhibitor Anle138b

[1]  Ixavier A. Higgins,et al.  Benchmarking causal reasoning algorithms for gene expression-based compound mechanism of action analysis , 2023, BMC Bioinformatics.

[2]  L. James,et al.  Cholesterol determines the cytosolic entry and seeded aggregation of tau , 2022, Cell reports.

[3]  D. Airey,et al.  A human tau seeded neuronal cell model recapitulates molecular responses associated with Alzheimer’s disease , 2022, Scientific Reports.

[4]  Maria-Anna Trapotsi,et al.  Computational analyses of mechanism of action (MoA): data, methods and integration , 2021, RSC chemical biology.

[5]  Avid M. Afzal,et al.  Systematic Analysis of Protein Targets Associated with Adverse Events of Drugs from Clinical Trials and Postmarketing Reports. , 2020, Chemical research in toxicology.

[6]  Michele Zagnoni,et al.  Quantitative propagation of assembled human Tau from Alzheimer's disease brain in microfluidic neuronal cultures , 2020, The Journal of Biological Chemistry.

[7]  Avid M. Afzal,et al.  Systematic analysis of protein targets associated with adverse events of drugs from clinical trials and post-marketing reports , 2020, bioRxiv.

[8]  R. Moyeed,et al.  Genetic networks in Parkinson’s and Alzheimer’s disease , 2020, Aging.

[9]  A. Giese,et al.  Effects of pharmacological modulators of α-synuclein and tau aggregation and internalization , 2020, Scientific Reports.

[10]  Z. Wen,et al.  Narrowing the Gap Between In Vitro and In Vivo Genetic Profiles by Deconvoluting Toxicogenomic Data In Silico , 2020, Frontiers in Pharmacology.

[11]  A. Hegde,et al.  Perturbations of Ubiquitin-Proteasome-Mediated Proteolysis in Aging and Alzheimer’s Disease , 2019, Front. Aging Neurosci..

[12]  Sushma,et al.  Role of GPCR signaling and calcium dysregulation in Alzheimer's disease , 2019, Molecular and Cellular Neuroscience.

[13]  L. Goldstein,et al.  Amyloid-β-independent regulators of tau pathology in Alzheimer disease , 2019, Nature Reviews Neuroscience.

[14]  A. Gamian,et al.  Targeted metabolomic analysis of nitric oxide/L-arginine pathway metabolites in dementia: association with pathology, severity, and structural brain changes , 2019, Scientific Reports.

[15]  S. Ziegler,et al.  Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer’s disease tau , 2019, Alzheimer's Research & Therapy.

[16]  V. Swarup,et al.  Integrative genomics approach identifies conserved transcriptomic networks in Alzheimer’s disease , 2019, bioRxiv.

[17]  H. Tanila,et al.  Altered Insulin Signaling in Alzheimer’s Disease Brain – Special Emphasis on PI3K-Akt Pathway , 2019, Front. Neurosci..

[18]  L. Goldstein,et al.  Cholesterol Metabolism Is a Druggable Axis that Independently Regulates Tau and Amyloid-β in iPSC-Derived Alzheimer’s Disease Neurons , 2019, Cell stem cell.

[19]  Andrea Volkamer,et al.  Advances and Challenges in Computational Target Prediction , 2019, J. Chem. Inf. Model..

[20]  Panuwat Trairatphisan,et al.  From expression footprints to causal pathways: contextualizing large signaling networks with CARNIVAL , 2019, npj Systems Biology and Applications.

[21]  Gautier Koscielny,et al.  Open Targets Platform: new developments and updates two years on , 2018, Nucleic Acids Res..

[22]  A. Giese,et al.  Anle138b modulates α‐synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy , 2018, Movement disorders : official journal of the Movement Disorder Society.

[23]  The Gene Ontology Consortium,et al.  The Gene Ontology Resource: 20 years and still GOing strong , 2018, Nucleic Acids Res..

[24]  J. Sáez-Rodríguez,et al.  Benchmark and integration of resources for the estimation of human transcription factor activities , 2018, bioRxiv.

[25]  T. Saido,et al.  Critical review: involvement of endoplasmic reticulum stress in the aetiology of Alzheimer's disease , 2018, Open Biology.

[26]  S. Müller,et al.  SUMO-specific proteases and isopeptidases of the SENP family at a glance , 2018, Journal of Cell Science.

[27]  Yan Xia,et al.  Predicting protein targets for drug-like compounds using transcriptomics , 2018, bioRxiv.

[28]  Luc Buée,et al.  Tau and neuroinflammation: What impact for Alzheimer's Disease and Tauopathies? , 2018, Biomedical journal.

[29]  Tim Clark,et al.  Tau induces blood vessel abnormalities and angiogenesis-related gene expression in P301L transgenic mice and human Alzheimer’s disease , 2018, Proceedings of the National Academy of Sciences.

[30]  G. Eichele,et al.  The diphenylpyrazole compound anle138b blocks Aβ channels and rescues disease phenotypes in a mouse model for amyloid pathology , 2017, EMBO molecular medicine.

[31]  Thawfeek M. Varusai,et al.  The Reactome Pathway Knowledgebase , 2017, Nucleic acids research.

[32]  Andreas Bender,et al.  Orthologue chemical space and its influence on target prediction , 2017, Bioinform..

[33]  Yoshihiro Yamanishi,et al.  Predicting inhibitory and activatory drug targets by chemically and genetically perturbed transcriptome signatures , 2018, Scientific Reports.

[34]  O. Gorbatyuk,et al.  Neurodegeneration: Keeping ATF4 on a Tight Leash , 2017, Front. Cell. Neurosci..

[35]  D. Salmon,et al.  Alzheimer’s Disease: Past, Present, and Future , 2017, Journal of the International Neuropsychological Society.

[36]  Glyn Bradley,et al.  CausalR: extracting mechanistic sense from genome scale data , 2017, Bioinform..

[37]  Lei Zhang,et al.  Analyzing the genes related to Alzheimer’s disease via a network and pathway-based approach , 2017, Alzheimer's Research & Therapy.

[38]  E. Mandelkow,et al.  Additional file 5: Figure S5. of The release and trans-synaptic transmission of Tau via exosomes , 2017 .

[39]  Alex Alves Freitas,et al.  A novel applicability domain technique for mapping predictive reliability across the chemical space of a QSAR: reliability-density neighbourhood , 2016, Journal of Cheminformatics.

[40]  Julio Saez-Rodriguez,et al.  OmniPath: guidelines and gateway for literature-curated signaling pathway resources , 2016, Nature Methods.

[41]  M. Garnett,et al.  Perturbation-response genes reveal signaling footprints in cancer gene expression , 2016, bioRxiv.

[42]  T. Hortobágyi,et al.  Tauopathy induced by low level expression of a human brain-derived tau fragment in mice is rescued by phenylbutyrate , 2016, Brain : a journal of neurology.

[43]  S. A. Hussaini,et al.  Neuronal activity enhances tau propagation and tau pathology in vivo , 2016, Nature Neuroscience.

[44]  Xinwen Zhou,et al.  The dual roles of cytokines in Alzheimer’s disease: update on interleukins, TNF-α, TGF-β and IFN-γ , 2016, Translational Neurodegeneration.

[45]  Vijaymeena M.K,et al.  A Survey on Similarity Measures in Text Mining , 2016 .

[46]  Guangchuang Yu,et al.  ReactomePA: an R/Bioconductor package for reactome pathway analysis and visualization. , 2016, Molecular bioSystems.

[47]  P. Szekeres,et al.  Short Fibrils Constitute the Major Species of Seed-Competent Tau in the Brains of Mice Transgenic for Human P301S Tau , 2016, The Journal of Neuroscience.

[48]  Chuen-Mao Yang,et al.  NF-kappaB Signaling Pathways in Neurological Inflammation: A Mini Review , 2015, Front. Mol. Neurosci..

[49]  C. Kaltschmidt,et al.  NF-KappaB in Long-Term Memory and Structural Plasticity in the Adult Mammalian Brain , 2015, Front. Mol. Neurosci..

[50]  Andreas Bender,et al.  Target prediction utilising negative bioactivity data covering large chemical space , 2015, Journal of Cheminformatics.

[51]  J. Renger,et al.  Internalized Tau Oligomers Cause Neurodegeneration by Inducing Accumulation of Pathogenic Tau in Human Neurons Derived from Induced Pluripotent Stem Cells , 2015, The Journal of Neuroscience.

[52]  B. Hyman,et al.  Neuronal uptake and propagation of a rare phosphorylated high-molecular-weight tau derived from Alzheimer's disease brain , 2015, Nature Communications.

[53]  S. Remy,et al.  Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies , 2015, Acta Neuropathologica.

[54]  P. Verstreken,et al.  Synaptic Contacts Enhance Cell-to-Cell Tau Pathology Propagation. , 2015, Cell reports.

[55]  Andrew N Hoofnagle,et al.  Arginine Deprivation and Immune Suppression in a Mouse Model of Alzheimer's Disease , 2015, The Journal of Neuroscience.

[56]  Douglas E. V. Pires,et al.  pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures , 2015, Journal of medicinal chemistry.

[57]  O. Garaschuk,et al.  Neuroinflammation in Alzheimer's disease , 2015, The Lancet Neurology.

[58]  D. Praticò,et al.  The 12/15-lipoxygenase as an emerging therapeutic target for Alzheimer's disease. , 2015, Trends in pharmacological sciences.

[59]  D. Praticò,et al.  The 12/15Lipoxygenase as an emerging therapeutic target for Alzheimer's disease , 2015 .

[60]  Aakash Chavan Ravindranath,et al.  Connecting gene expression data from connectivity map and in silico target predictions for small molecule mechanism-of-action analysis. , 2015, Molecular bioSystems.

[61]  H. Mansvelder,et al.  Reducing hippocampal extracellular matrix reverses early memory deficits in a mouse model of Alzheimer’s disease , 2014, Acta neuropathologica communications.

[62]  A. Jain,et al.  Human CDC2-like kinase 1 (CLK1): a novel target for Alzheimer's disease. , 2014, Current drug targets.

[63]  K. Bötzel,et al.  The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset , 2014, Acta Neuropathologica.

[64]  J. Winderickx,et al.  Neuron-to-neuron wild-type Tau protein transfer through a trans-synaptic mechanism: relevance to sporadic tauopathies , 2014, Acta neuropathologica communications.

[65]  W. Hsu,et al.  STAT1 Negatively Regulates Spatial Memory Formation and Mediates the Memory-Impairing Effect of Aβ , 2013, Neuropsychopharmacology.

[66]  C. Dickey,et al.  Potential synergy between tau aggregation inhibitors and tau chaperone modulators , 2013, Alzheimer's Research & Therapy.

[67]  P. Tavan,et al.  Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease , 2013, Acta Neuropathologica.

[68]  D. Rubinsztein,et al.  The role of membrane-trafficking small GTPases in the regulation of autophagy , 2013, Journal of Cell Science.

[69]  C. Zurzolo,et al.  Small Misfolded Tau Species Are Internalized via Bulk Endocytosis and Anterogradely and Retrogradely Transported in Neurons* , 2012, The Journal of Biological Chemistry.

[70]  Andreas Bender,et al.  From in silico target prediction to multi-target drug design: current databases, methods and applications. , 2011, Journal of proteomics.

[71]  Honglian Shi,et al.  Hypoxia inducible factor-1 as a target for neurodegenerative diseases. , 2011, Current medicinal chemistry.

[72]  Matko Bosnjak,et al.  REVIGO Summarizes and Visualizes Long Lists of Gene Ontology Terms , 2011, PloS one.

[73]  B. Strooper,et al.  The role of G protein-coupled receptors in the pathology of Alzheimer's disease , 2011, Nature Reviews Neuroscience.

[74]  J. Caboche,et al.  Elk-1 a Transcription Factor with Multiple Facets in the Brain , 2011, Front. Neurosci..

[75]  P. Dolan,et al.  The role of tau kinases in Alzheimer's disease. , 2010, Current opinion in drug discovery & development.

[76]  Serban Nacu,et al.  Fast and SNP-tolerant detection of complex variants and splicing in short reads , 2010, Bioinform..

[77]  M. Figueiredo-Pereira,et al.  Relationship between tau pathology and neuroinflammation in Alzheimer's disease. , 2010, The Mount Sinai journal of medicine, New York.

[78]  S. DeKosky,et al.  Is the urea cycle involved in Alzheimer's disease? , 2010, Journal of Alzheimer's Disease.

[79]  W. Noble,et al.  Linking Amyloid and Tau Pathology in Alzheimer's Disease: The Role of Membrane Cholesterol in Aβ-Mediated Tau Toxicity , 2009, The Journal of Neuroscience.

[80]  Y. Wong,et al.  G protein‐coupled receptor‐induced Akt activity in cellular proliferation and apoptosis , 2007, The FEBS journal.

[81]  Shinichiro Yamamoto,et al.  Transient receptor potential channels in Alzheimer's disease. , 2007, Biochimica et biophysica acta.

[82]  J. Gutkind,et al.  G-protein-coupled receptors and cancer , 2007, Nature Reviews Cancer.

[83]  N. Hitzeman.  Cholinesterase inhibitors for Alzheimer's disease. , 2006, American family physician.

[84]  K. Blennow,et al.  The link between cholesterol and Alzheimer's disease , 2005, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[85]  Paul T. Groth,et al.  The ENCODE (ENCyclopedia Of DNA Elements) Project , 2004, Science.

[86]  Hong Wang,et al.  Glutathione Metabolism during Aging and in Alzheimer Disease , 2004, Annals of the New York Academy of Sciences.

[87]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[88]  K. Davis.  Cholinesterase Inhibitors in Alzheimer's Disease , 1994, Neuropsychopharmacology.

[89]  P. Davies,et al.  A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. , 1990, Proceedings of the National Academy of Sciences of the United States of America.